New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 23, 2014
07:54 EDTABBV, SHPGAbbVie may raise Shire bid up to GBP 55 per share, says Jefferies
Jefferies believes AbbVie (ABBV) can materially raise its takeover bid for Shire (SHPG), but it thinks inversion risk is likely to cap the offer at GBP 55 per share. The firm says earnings accretion and cash flow benefits from acquiring Shire could be higher than investors appreciate and it keeps a Buy rating on AbbVie with a $66 price target.
News For SHPG;ABBV From The Last 14 Days
Check below for free stories on SHPG;ABBV the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
July 25, 2014
09:17 EDTABBVAbbVie sees FY14 global Humira sales to see double digit growth
Subscribe for More Information
07:50 EDTABBVAbbVie reports Q2 Global HUMIRA sales up 26.2% to $3.29B
Total company sales growth was also driven by strong growth from key products including Synthroid, Sevoflurane and Duodopa.
07:48 EDTABBVAbbVie sees Q3 adjusted EPS 77c-79c, consensus 77c
07:48 EDTABBVAbbVie backs FY14 adjustd EPS $3.06-$3.16, consensus $3.14
Subscribe for More Information
07:47 EDTABBVAbbVie reports Q2 adjusted EPS 82c, consensus 76c
Subscribe for More Information
07:31 EDTABBVEMA recommends expanded indication for Humira
Subscribe for More Information
July 24, 2014
12:56 EDTABBVPerrigo confirms AB therapeutic equivalent rating for testosterone gel 1.0%
Subscribe for More Information
July 23, 2014
11:21 EDTSHPGOptions with decreasing implied volatility
Options with decreasing implied volatility: INO SHPG IRBT CMG LXK PSEC CROX ATHN VMW
07:28 EDTSHPGShire enters licensing and collaboration agreement with ArmaGen
Shire and ArmaGen, a US privately held biotechnology company, announced a worldwide licensing and collaboration agreement for AGT-182, an investigational enzyme replacement therapy for the potential treatment of both the central nervous system and somatic manifestations in patients with Hunter syndrome. Shire will obtain worldwide commercialization rights for AGT-182 in exchange for payments of approximately $225M to ArmaGen, including an initial upfront payment of $15M in cash and equity, an additional equity investment, R&D funding, development milestones and sales milestones, in addition to royalty payments. ArmaGen will be responsible for conducting and completing the Phase I/II study which it expects to initiate before the end of 2014, after which point Shire will be responsible for further clinical development, including Phase III trials, and commercialization.
06:01 EDTSHPGStocks with implied volatility below IV index mean; INTC SHPG
Stocks with implied volatility below IV index mean; Intel (INTC) 18, Shire (SHPG) 19 according to iVolatility.
July 22, 2014
10:48 EDTSHPGOptions with decreasing implied volatility
Options with decreasing implied volatility: IGT YHOO LYK ATHN CMG SWKS NFLX SHPG SNDK MTG
05:59 EDTSHPGStocks with implied volatility below IV index mean; INTC SHPG
Subscribe for More Information
July 21, 2014
10:27 EDTSHPG, ABBVUBS pharma and federal affairs analysts hold an analyst/industry conference call
Subscribe for More Information
10:02 EDTSHPGOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:50 EDTSHPGShire downgraded to Neutral from Buy at Buckingham
Subscribe for More Information
08:01 EDTSHPG, ABBVAbbVie acquisition positive, says Argus
Subscribe for More Information
07:59 EDTSHPG, ABBVShire downgraded to Market Perform from Outperform at Leerink
Leerink downgraded Shire (SHPG) on Friday to Market Perform citing the takeover by AbbVie (ABBV) as it does not expect competitive bids to emerge.
06:43 EDTABBVGrowing market for hepatitis-C treatment prompts legal scramble, WSJ says
Subscribe for More Information
06:14 EDTSHPGStocks with implied volatility below IV index mean; INTC SHPG
Subscribe for More Information
06:10 EDTABBVStocks with implied volatility movement; ABBV JOY
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use